Novartis profits
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.NOVARTIS, the world's largest healthcare company, said first-half earnings rose 14 per cent as rising income from investments more than offset stagnant operating profits. The company said it will sell low-margin nutrition brands to raise profitability.
Net income at the maker of blockbuster transplant drug Neoral and Ciba Vision eye-care products rose to Sfr3.6bn (pounds 1.5bn) from Sfr3.1bn. Investment income jumped fivefold, while operating profits were little changed on higher marketing costs.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments